The MedAnnex management team has an impressive track record within the biopharmaceutical industry, including the formation and growth of Bioenvision Inc. into a NASDAQ National listed, global biopharmaceutical company, which was acquired in October 2007 by Genzyme Corporation.

MedAnnex has recently secured an investment, led by Alida Capital International, which will take annexuzlimab through to clinical development.

Latest News

March 2018

The application process is now open for the MedAnnex/University of Glasgow four-year PhD, "Annexin-A1 as a target for T cell mediated pathology in psoriatic arthritis”

February 2018

MedAnnex welcomes Prof Carl Goodyear to its┬áScientific Advisory Board. Carl is Professor of Translational Immunology at Glasgow University’s Institute of Infection, Immunity and Inflammation, and Director of the GLAZgo Discovery Centre.